Literature DB >> 20382708

Increased biglycan in aortic valve stenosis leads to the overexpression of phospholipid transfer protein via Toll-like receptor 2.

Habib Derbali1, Yohan Bossé, Nancy Côté, Philippe Pibarot, Audrey Audet, Andree Pépin, Benoit Arsenault, Christian Couture, Jean-Pierre Després, Patrick Mathieu.   

Abstract

Aortic stenosis (AS) is the most common valvular heart disease, and it is suspected that atherosclerotic mechanisms are involved in the development of this disorder. Therefore, the retention of lipids within the aortic valve may play a role in the pathobiology of AS. In this study, a gene expression microarray experiment was conducted on human aortic valves with and without AS. The expression levels of transcripts encoding proteoglycans and enzymes involved in lipid retention were compared between the two groups. The microarray results were subsequently replicated in a cohort of 87 AS valves and 36 control valves. In addition, the interaction between proteoglycan and lipid-modifying enzyme was documented in isolated valve interstitial cells (VICs). The microarray results indicated that only biglycan (BGN) and phospholipid transfer protein (PLTP) were overexpressed in the AS valves. These results were then confirmed by quantitative PCR. The immunohistochemical analysis revealed a colocalization of BGN, PLTP, and Toll-like receptor-2 (TLR 2) in AS valves. In vitro, we showed that BGN induces the production of PLTP in VICs via the stimulation of TLR 2. Thus, increased accumulation of BGN in AS valves contributes to the production of PLTP via TLR 2. These results suggest that intricate links between valve matrix proteins, inflammation, and lipid retention are involved in the pathobiology of AS.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20382708      PMCID: PMC2877827          DOI: 10.2353/ajpath.2010.090541

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  24 in total

1.  Variations in oxidative susceptibility among six low density lipoprotein subfractions of differing density and particle size.

Authors:  D L Tribble; L G Holl; P D Wood; R M Krauss
Journal:  Atherosclerosis       Date:  1992-04       Impact factor: 5.162

2.  Accumulation of biglycan and perlecan, but not versican, in lesions of murine models of atherosclerosis.

Authors:  Vidya V Kunjathoor; Diane S Chiu; Kevin D O'Brien; Renée C LeBoeuf
Journal:  Arterioscler Thromb Vasc Biol       Date:  2002-03-01       Impact factor: 8.311

3.  Toll-like receptor-4 is expressed by macrophages in murine and human lipid-rich atherosclerotic plaques and upregulated by oxidized LDL.

Authors:  X H Xu; P K Shah; E Faure; O Equils; L Thomas; M C Fishbein; D Luthringer; X P Xu; T B Rajavashisth; J Yano; S Kaul; M Arditi
Journal:  Circulation       Date:  2001-12-18       Impact factor: 29.690

Review 4.  The response-to-retention hypothesis of early atherogenesis.

Authors:  K J Williams; I Tabas
Journal:  Arterioscler Thromb Vasc Biol       Date:  1995-05       Impact factor: 8.311

5.  Smooth muscle cell biglycan overexpression results in increased lipoprotein retention on extracellular matrix: implications for the retention of lipoproteins in atherosclerosis.

Authors:  Kevin D O'Brien; Katherine Lewis; Jens W Fischer; Pamela Johnson; Jin-Yong Hwang; Eleanor A Knopp; Michael G Kinsella; P Hugh R Barrett; Alan Chait; Thomas N Wight
Journal:  Atherosclerosis       Date:  2004-11       Impact factor: 5.162

6.  Cell-associated and extracellular phospholipid transfer protein in human coronary atherosclerosis.

Authors:  Kevin D O'Brien; Simona Vuletic; Thomas O McDonald; Gertrud Wolfbauer; Katherine Lewis; An-Yue Tu; Santica Marcovina; Thomas N Wight; Alan Chait; John J Albers
Journal:  Circulation       Date:  2003-06-30       Impact factor: 29.690

7.  Phospholipid transfer protein is present in human atherosclerotic lesions and is expressed by macrophages and foam cells.

Authors:  Catherine M Desrumaux; Puiying A Mak; William A Boisvert; David Masson; Dwayne Stupack; Matti Jauhiainen; Christian Ehnholm; Linda K Curtiss
Journal:  J Lipid Res       Date:  2003-05-01       Impact factor: 5.922

8.  Increased atherosclerotic lesions in apoE mice with plasma phospholipid transfer protein overexpression.

Authors:  Xiao Ping Yang; Daoguang Yan; Chunping Qiao; Rui Jie Liu; Jer-Gin Chen; Juan Li; Martina Schneider; Laurent Lagrost; Xiao Xiao; Xian-Cheng Jiang
Journal:  Arterioscler Thromb Vasc Biol       Date:  2003-07-10       Impact factor: 8.311

9.  Elevation of plasma phospholipid transfer protein increases the risk of atherosclerosis despite lower apolipoprotein B-containing lipoproteins.

Authors:  Jessica Lie; Rini de Crom; Teus van Gent; Rien van Haperen; Leo Scheek; Farah Sadeghi-Niaraki; Arie van Tol
Journal:  J Lipid Res       Date:  2004-03-01       Impact factor: 5.922

Review 10.  Mechanism of lipoprotein retention by the extracellular matrix.

Authors:  Maria Gustafsson; Jan Borén
Journal:  Curr Opin Lipidol       Date:  2004-10       Impact factor: 4.776

View more
  29 in total

Review 1.  Small leucine-rich proteoglycans orchestrate receptor crosstalk during inflammation.

Authors:  Kristin Moreth; Renato V Iozzo; Liliana Schaefer
Journal:  Cell Cycle       Date:  2012-06-01       Impact factor: 4.534

2.  Aortic stenosis is largely a boney affair.

Authors:  Friedrich C Luft
Journal:  J Mol Med (Berl)       Date:  2015-04       Impact factor: 4.599

3.  Altered versican cleavage in ADAMTS5 deficient mice; a novel etiology of myxomatous valve disease.

Authors:  Loren E Dupuis; Daniel R McCulloch; Jessica D McGarity; Alexandria Bahan; Andy Wessels; Deidra Weber; A Megan Diminich; Courtney M Nelson; Suneel S Apte; Christine B Kern
Journal:  Dev Biol       Date:  2011-07-01       Impact factor: 3.582

Review 4.  Molecular and cellular aspects of calcific aortic valve disease.

Authors:  Dwight A Towler
Journal:  Circ Res       Date:  2013-07-05       Impact factor: 17.367

Review 5.  Proteoglycans in health and disease: novel regulatory signaling mechanisms evoked by the small leucine-rich proteoglycans.

Authors:  Renato V Iozzo; Liliana Schaefer
Journal:  FEBS J       Date:  2010-08-31       Impact factor: 5.542

6.  Inflammation is associated with the remodeling of calcific aortic valve disease.

Authors:  Nancy Coté; Ablajan Mahmut; Yohan Bosse; Christian Couture; Sylvain Pagé; Sylvain Trahan; Marie-Chloé Boulanger; Dominique Fournier; Philippe Pibarot; Patrick Mathieu
Journal:  Inflammation       Date:  2013-06       Impact factor: 4.092

7.  De novo expression of circulating biglycan evokes an innate inflammatory tissue response via MyD88/TRIF pathways.

Authors:  Jinyang Zeng-Brouwers; Janet Beckmann; Madalina-Viviana Nastase; Renato V Iozzo; Liliana Schaefer
Journal:  Matrix Biol       Date:  2013-12-18       Impact factor: 11.583

Review 8.  Calcific aortic stenosis.

Authors:  Brian R Lindman; Marie-Annick Clavel; Patrick Mathieu; Bernard Iung; Patrizio Lancellotti; Catherine M Otto; Philippe Pibarot
Journal:  Nat Rev Dis Primers       Date:  2016-03-03       Impact factor: 52.329

9.  Biglycan induces the expression of osteogenic factors in human aortic valve interstitial cells via Toll-like receptor-2.

Authors:  Rui Song; Qingchun Zeng; Lihua Ao; Jessica A Yu; Joseph C Cleveland; Ke-Seng Zhao; David A Fullerton; Xianzhong Meng
Journal:  Arterioscler Thromb Vasc Biol       Date:  2012-09-13       Impact factor: 8.311

10.  Soluble biglycan induces the production of ICAM-1 and MCP-1 in human aortic valve interstitial cells through TLR2/4 and the ERK1/2 pathway.

Authors:  Rui Song; Lihua Ao; Ke-Seng Zhao; Daniel Zheng; Neil Venardos; David A Fullerton; Xianzhong Meng
Journal:  Inflamm Res       Date:  2014-05-30       Impact factor: 4.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.